Doug Schirle
Analyst · Carl M. Hennig
Thank you Didier. For the fiscal year ended March 31 2021, we reported a net loss of $21.5 million or $0.91 per diluted share, a net revenues of $27.7 million, a net loss of $10.3 million or $0.45 per diluted share, a net revenues of $43.3 million in the fiscal year ended March 31 2020. Gross margin for fiscal 2021 was 47.7% compared to 58.5% in the prior year. Total operating expenses were $34.5 million in fiscal 2021, a decrease of 4.6% from $36.1 million in fiscal 2020. Research and development expenses were $23.3 million compared to $25.2 million in the prior fiscal year. And selling general and administrative expenses were $11.1 million compared to $10.9 million in fiscal 2020. The decrease in research and development expense was primarily due to a charge of $2.7 million during the third quarter of fiscal 2020 for purchased intellectual property that is being incorporated into our next-generation of Gemini chips. Fiscal 2021 operating loss was $21.3 million compared to an operating loss of $10.8 million in the prior year. The increase in operating loss is primarily due to the decrease in revenue and gross profit. Fiscal 2021, net loss included interest and other income of $94,000 and a cash provision of $335,000 compared to $712,000 of interest and other income and a tax provision of $247,000 a year ago. The company reported a net loss of $5 million or $0.21 per diluted share and net revenues of $7.7 million for the fourth quarter of fiscal 2021, compared to a net loss of $3.8 million or $0.16 per diluted share and net revenues of $8.5 million for the fourth quarter of fiscal 2020 and a net loss of $5.2 million or $0.22 per diluted share and net revenues of $6.8 million in the third quarter of fiscal 2021. Gross margin was 50.2% compared to 52.5% in the prior year period and 47.3% in the preceding third quarter. The change in gross margin was primarily due to changes in the mix of products sold and the negative impact of manufacturing overhead and reduced revenues. Total operating expenses in the fourth quarter of fiscal 2021 were $9.1 million compared to $8.4 million in the fourth quarter in fiscal 2020 and $8.3 million in the prior quarter. Research and development expenses were $6.1 million compared to $5.6 million in the prior year period and $5.7 million in the prior quarter. Selling, general and administrative expenses were $3 million in the quarter ended March 31 2021, compared to $2.8 million in the prior year quarter and $2.6 million in the previous quarter. Fourth quarter fiscal 2021 operating loss was $5.3 million, compared to an operating loss of $3.9 million in the prior year period and an operating loss of $5.2 million from the prior quarter. Fourth quarter fiscal 2021 net loss included interest and other expense of $21,000 and a tax benefit of $304,000 compared to $148,000 in interest and other income and a tax provision of $65,000 for the same period a year ago. In the preceding third quarter, net loss included interest and other income of $25,000 and a tax provision of $90,000. Total fourth quarter pre-tax stock-based compensation expense was $753,000 compared to $644,000 in the comparable quarter a year ago and $693,000 in the prior quarter. At March 31 2021, we had $54 million in cash, cash equivalents and short-term investments and $5.8 million in long-term investments, compared to $66.6 million in cash, cash equivalents and short-term investments of $4.1 million in long-term investments at March 31 2020. Working capital was $56 million at March 31 2021, compared to $70.9 million at March 31 2020 with no debt. Stockholders' equity as of March 31, 2021 was $75.6 million compared to $89.6 million as of the fiscal year ended March 31, 2020. Fourth quarter net revenues and gross margin were within the range of guidance provided in our last earnings release for net revenue in the range of $6.8 million to $7.8 million with gross margin above the range of approximately 48% to 52%. Our current expectations for the upcoming quarter are net revenues in the range of $8.1 million to $9.1 million with gross margin of approximately 54% to 56%. Our Board of Directors has authorized us to repurchase at management's discretion shares of our common stock. Under the repurchase program, we may repurchase shares from time-to-time on open market or in private transactions. Pacific timing and amount of the repurchases will be dependent on market conditions, security law limitations and other factors. The repurchase program may be suspended or terminated at any time without prior notice. To date, we have repurchased a total of 12,004,779 shares including 3.8 million shares acquired for purchase -- at a purchase price of $6.50 per share under Dutch -- under a modified Dutch auction self tender offer completed in August 2014. Our repurchases have been at an average cost of $5.06 per share for a total cost of $60.7 million, compared to net proceeds of approximately $30 million in our IPO in March 2007. On March 31, 2021, management was authorized to repurchase additional shares of our common stock with a value of up to $4.3 million under the repurchase program. We have continuously had active programs to repurchase shares, but our repurchase price has been too low to purchase shares. Given the uncertainty in the economy, rising manufacturing prices and the uncertainty of when Gemina APU and Rad-Hard, Rad-Tolerant products will generate significant revenues we are in a cash conservation mode. Operator, at this point we will open the call to Q&A.